NRC	FΩ	ВM	374
14170	$-\mathbf{c}$	LAIN	317

U.S. NUCLEAR REGULATORY COMMISSION

AGE <u>1</u> OF <u>4</u> PAGES

Amendment No. 27

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below

below.	0212C	<i>)</i>	5/60	
Licensee		In accordance with	the letters date	d
		November 18, 201	1, and Decemb	per 14, 2011,
Midwest Division - LSH, LLC (d/b/a Lee's Summit Hospital)		3. License number 24 entirety to read as f		nended in its
2. 2100 S.E. Blue Parkway		4. Expiration date O	october 31, 201	<u> </u>
Lee's Summit, MO 64063		5. Docket No. 030-29 Reference No.	9074	
Byproduct, source, and/or special 7 nuclear material	. Chemical and/or ph	ysical form 8.		that licensee may ne time under this
Any byproduct material permitted by 10 CFR 35.100	A. Any		A. As needed	
B. Any byproduct material permitted by 10 CFR 35.200	B. Any		B. As needed	3
C. Any byproduct material permitted by 10 CFR 35.300	C. Any		*	d (Not to exceed of iodine-131)
D. Any byproduct material permitted by 10 CFR 31.11	D. Prepackage	ed Kits	D. 2 millicurie	es e e e e e e e e e e e e e e e e e e
<u>.ea.</u>	+ ()			

9. Authorized Use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. <u>In vitro</u> studies.

CONDITIONS

- 10. Licensed material may be used or stored only at the licensee's facilities located at 2100 S.E. Blue Parkway, Lee's Summit, Missouri.
- 11. The Radiation Safety Officer for this license is Robert F. Thompson, Ph.D.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE	2	of	4	PAGES
		License Number 24-24660-01					
	MATERIALS LICENSE SUPPLEMENTARY SHEET	Docket or Reference Number 030-29074	•				
		Amendment No. 27					
				_			

- 12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for the materials and uses indicated:

Authorized Users	Material and Use
Robert G. Schwegler, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
John E. Scott, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
William M. Chase, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Craig M. Bruner, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Douglas W. Nemmers, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Michael B. Parsa, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Jeffrey R. Conaway, M.D.	10 CFR 35.100, 35.200 and 35.300.
John F. Eurich, M.D.	10 CFR 35.100, 35.200 and 35.300.
William Brooks, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Ira Cox, M.D.	10 CFR 35.100, 35.200, 35.300 and31.11.
Kelly Hart, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Rick Moritz, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Thomas Zinn, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
William B. Davis, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Sarah L. Sherard, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Donald J. Stallard, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Daniel H. Dunker, M.D.	10 CFR 35.200.
James E. Sear, M.D.	10 CFR 35.200:
Michael Brian Robertson, M.D.	10 CFR 31.11.
Bradley McIlnay, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Vandana Halder, M.D.	10 CFR 35.100, 35.200 and 35.300.

MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 24-24660-01 Docket or Reference Number 030-29074
·	Amendment No. 27
<u>Authorized Users</u>	Material and Use
Leo J. Splitter, M.D.	10 CFR 35.100, 35.200 and 35.300.
Craig B. McClure, M.D.	10 CFR 35.100 and 35.200.
Robert A. Wood, Jr., M.D.	10 CFR 35.100, 35.200 and 35.300.
Joseph Philip Koury, M.D.	10 CFR 35.100 and 35.200.
Wendall Doronio, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to sodium iodide iodine-131 in quantities less than or equal to 33 millicuries).
Jason Eric Himmel, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to sodium iodide iodine-131 in quantities less than or equal to 33 millicuries).
Michael J. Brigg, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to the use of sodium iodide iodine-131).
Nathaniel R. Jewell, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to the use of sodium iodide iodine-131).
Richard Cronemeyer, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries).
David Hazuka, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide iodine-131).
Christopher McKinney, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries).
Robert Thompson, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide iodine-131).
Aaron M. Lewis, M.D.	10 CFR 35.100, 35.200 and 35.300.
David M. Penn, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries).

U.S. NUCLEAR REGULATORY COMMISSION

PAGE

License Number

3

of 4

PAGES

NRC FORM 374A

- 13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
- 14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
- 15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
 - A. Application received April 6, 2001 (with attachments); and
 - B. Letters dated March 26, 2003, April 15, 2003 (with enclosure), November 18, 2008, and February 17, 2009 (with enclosed close-out survey).

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

FEB 0 8 2012

Toye L. Simmons

Materials Licensing Branch

Region IIII

Date